Quick Answer
Immunome Inc. reported Net Income Loss of -$212.39 million for the year ending 2025.
- Immunome Inc. showed an increase of +27.5% in Net Income Loss from 2024 to 2025.
- This data is from Immunome Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Immunome Inc.'s Net Income Loss has declined by 1,933.6%.
- Historical annual values: Fiscal year 2025: -$212.39 million | Fiscal year 2024: -$292.96 million | Fiscal year 2023: -$106.81 million | Fiscal year 2022: -$36.90 million | Fiscal year 2021: -$24.71 million | Fiscal year 2020: -$17.84 million | Fiscal year 2019: -$10.44 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: